A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.

Arthritis and rheumatism

Volumn 64, Issue 4, 2012, Pages 970-981

  Kremer, Joel M ^a   Cohen, Stanley ^b   Wilkinson, Bethanie E ^b   Connell, Carol A ^b   French, Jonathan L ^b   Gomez Reino, Juan ^b   Gruben, David ^b   Kanik, Keith S ^b   Krishnaswami, Sriram ^b   Pascual Ramos, Virginia ^b   Wallenstein, Gene ^b   Zwillich, Samuel H ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TOFACITINIB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84866156845     PISSN: None     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33419     Document Type: Article

References (0)